

Samit Ghosal<sup>1</sup>, Surekha Tippisetty<sup>2</sup>, Subhadra Polisetti<sup>2</sup>, Krishna G. Seshadri<sup>3</sup>

<sup>1</sup>Department of Endocrinology, Nightingale Hospital, Kolkata, West Bengal, India

<sup>2</sup>Department of Medical Research, Medswan Global Healthtech Private Limited, Hyderabad, Telangana, India

<sup>3</sup>Department of Endocrinology, Chennai Diabetes and Endocrinology Clinic, Chennai, Tamil Nadu, India

# Metformin for the Prevention of Prediabetes Progression to Type 2 Diabetes: A Systematic Review and Meta-Analysis

## Editor's note:

The meta-analysis included data from eight randomized trials (Figure 2). Four out of eight trials were subgroup or subset of the same study (US Diabetes Prevention Program). This duplication of data has resulted in a conclusion that could not be supported when those four studies were excluded from the analysis. Authors agreed to Journal' decision on retracting this paper.

## Applies to the article:

Ghosal S, Tippisetty S, Polisetti S, et al. Metformin for the Prevention of Prediabetes Progression to Type 2 Diabetes: A Systematic Review and Meta-Analysis. Clin. Diabetol. 2024; DOI: 10.5603/cd.99821.

This letter was published July 26, 2024.